Understanding the Setup: (AVTR) and Scalable Risk
This article analyzes Avantor Inc. (AVTR), identifying a near-term neutral sentiment but suggesting a pause in its mid and long-term weakness. It highlights an exceptional risk-reward short setup with significant downside potential against minimal risk. The analysis provides institutional trading strategies for long, breakout, and short positions, based on AI-generated signals and multi-timeframe analysis.
Avantor (AVTR): Buy, Sell, or Hold Post Q1 Earnings?
Avantor (AVTR) has seen a significant stock drop of 30.3% over the last six months, trading at $7.66 per share. The article expresses a lack of confidence in Avantor's future performance due to declining organic revenue, stalled projected revenue growth, and a downward trend in EPS. Despite an "optically cheap" valuation, the analysis concludes that Avantor has shaky fundamentals and recommends avoiding the stock.
Avantor, Inc. Appoints Gerard Porreca as Executive Vice President, Quality and Regulatory
Avantor, Inc. has appointed Gerard (Jerry) Porreca as its new Executive Vice President, Quality and Regulatory. In this role, Mr. Porreca will be responsible for global quality assurance, quality systems, and regulatory affairs across all of Avantor's businesses. He brings extensive experience from previous senior roles at companies like Getinge, Becton Dickinson and Company, C.R. Bard, Inc., and Smith+Nephew plc, where he focused on quality, regulatory affairs, and compliance in the life sciences and medical technology sectors.
Press Release: Avantor(R) Announces Gerard (Jerry) Porreca as Executive Vice President, Quality and Regulatory
Avantor has announced the appointment of Gerard (Jerry) Porreca as Executive Vice President, Quality and Regulatory, effective June 10, 2024. In this role, Porreca will oversee Avantor's global quality assurance, quality control, regulatory affairs, and environmental, health, and safety organizations. His appointment aims to enhance Avantor's commitment to quality and regulatory compliance in its high-performance product and solutions portfolio.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Avantor, Inc. (AVTR) and Encourages Stockholders to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Avantor, Inc. (AVTR) and its officers/directors for potential corporate wrongdoing. The firm encourages investors who purchased Avantor securities before March 5, 2024, and continue to hold them, to join the investigation. Bronstein, Gewirtz & Grossman, LLC operates on a contingency fee basis, aiming to recover investor capital and ensure corporate accountability.
Global Cell Culture Media Market Outlook 2026-2036: Biologics Manufacturing and Cell Therapy Expansion Accelerate Growth for Avantor, Thermo Fisher Scientific, and Lonza Group AG
The global Cell Culture Media Market is projected to grow from USD 3.7 billion in 2026 to USD 7.1 billion by 2036, driven by rising biologics production, expanding cell and gene therapy pipelines, and increasing adoption of serum-free formulations. Key players like Avantor, Thermo Fisher Scientific, and Lonza Group AG are focusing on scalable GMP production and advanced media platforms to meet demand. The serum-free media segment and cancer research application are expected to lead market growth, with China, Japan, and Germany showing the fastest regional expansion.
Avantor appoints Gerard Porreca as quality and regulatory EVP
Avantor Inc. has announced the appointment of Gerard Porreca as Executive Vice President, Quality and Regulatory. Porreca will oversee global quality assurance, quality systems, and regulatory affairs across all of Avantor's businesses. This strategic hire follows Avantor's strong Q1 2026 financial performance, where it surpassed analyst expectations for both EPS and revenue.
Avantor hands global quality and regulatory oversight to new EVP Jerry Porreca
Avantor (NYSE: AVTR) has appointed Gerard (Jerry) Porreca as Executive Vice President, Quality and Regulatory, effective May 19, 2026. In this role, he will oversee global quality assurance, quality systems, and regulatory affairs across all Avantor businesses. Porreca brings extensive experience from previous senior roles at Getinge, Becton Dickinson, C.R. Bard, and Smith+Nephew, which Avantor expects will be crucial for scaling operations and maintaining high standards for its life sciences and advanced technology customers.
Avantor Announces Gerard (Jerry) Porreca as Executive Vice President, Quality and Regulatory
Avantor, Inc. has announced the appointment of Gerard (Jerry) Porreca as Executive Vice President, Quality and Regulatory. In this role, Mr. Porreca will oversee global quality assurance, quality systems, and regulatory affairs for all Avantor's businesses. He brings extensive experience from previous leadership positions at Getinge, Becton Dickinson and Company, C.R. Bard, Inc., and Smith+Nephew plc, enhancing Avantor's commitment to high standards in the life sciences and advanced technology sectors.
Avantor’s SWOT analysis: life sciences stock faces mounting pressures
Avantor (NYSE:AVTR), a life sciences tools and services provider, is facing significant challenges, leading to major investment firms downgrading its stock. The company's third-quarter 2025 performance missed expectations, with revenue and gross margin shortfalls, and its stock has plummeted over 43% in the past year. A strategic review is underway to address competitive pressures, operational issues, and reduced financial guidance, raising questions about its near-term recovery prospects.
Avantor (AVTR) Fell as Destocking Has Lasted Longer Than Expected
Broyhill Asset Management reported that its investment in Avantor, Inc. (AVTR) was a detractor in Q1 2026, primarily due to a longer-than-expected destocking cycle and management's failure to compete with Thermo Fisher. The firm has since redeployed its capital from Avantor into Sotera Health. Despite Avantor's revenue of $1.58 billion in Q1 2026, hedge fund interest in the company has decreased.
Avantor (AVTR) Fell as Destocking Has Lasted Longer Than Expected
Broyhill Asset Management's first-quarter 2026 investor letter revealed that Avantor, Inc. (NYSE:AVTR) contributed negatively to their portfolio. The firm noted that the destocking cycle for Avantor has extended beyond initial models, and management failed to defend its market share against competitors like Thermo Fisher. Broyhill Asset Management ultimately redeployed capital from Avantor into Sotera Health, citing better opportunities despite litigation fears.
Avantor stock (US0543031027): focus shifts to margin recovery after Q1 earnings
Avantor has reported its first-quarter 2026 earnings, showing improving profitability and stabilizing demand in its key markets. The company, a global supplier of life science products and services, is focusing on margin recovery after shifts in demand post-pandemic. This article details Avantor's business model, key revenue drivers, and insights for US investors regarding its market exposure and financial performance.
Avantor's Turnaround Story Ongoing, Execution Risks Remain, RBC Says
RBC Capital Markets highlighted that Avantor's turnaround efforts are still in progress, indicating that while progress is being made, significant execution risks persist. The firm's analysis likely details the challenges and opportunities for Avantor as it navigates its strategic changes. Investor caution is advised due to these ongoing risks.
RBC Capital assumes Avantor stock coverage with $9 target By Investing.com
RBC Capital has initiated coverage on Avantor Inc. (NYSE:AVTR) with a Sector Perform rating and a $9.00 price target. The firm views the management turnaround efforts positively, though execution challenges remain, and notes the stock is currently trading below the target at $7.94, while InvestingPro data suggests a fair value of $10.30. Avantor recently reported stronger-than-expected Q1 2026 financial results, with EPS of $0.17 and revenue of $1.581 billion, exceeding analyst forecasts.
RBC Capital assumes Avantor stock coverage with $9 target
RBC Capital has initiated coverage on Avantor Inc. (NYSE:AVTR) with a Sector Perform rating and a $9.00 price target. The firm sees a positive management turnaround effort balanced against remaining execution challenges, noting the stock's valuation implies a strong free cash flow yield despite recent downward earnings revisions by analysts. This comes after Avantor reported strong first-quarter 2026 financial results, exceeding both EPS and revenue expectations.
RBC Capital assumes Avantor stock coverage with $9 target By Investing.com
RBC Capital has initiated coverage on Avantor Inc. (NYSE:AVTR) with a Sector Perform rating and a $9.00 price target. The firm noted a positive view of management's turnaround efforts despite execution challenges, and that the stock is currently undervalued according to InvestingPro data with a Fair Value of $10.30. Avantor recently reported strong Q1 2026 financial results, exceeding EPS and revenue forecasts, which has garnered positive investor attention.
Avantor Shareholders Approve Proposals at 2026 Annual Meeting
Avantor, Inc. held its 2026 Annual Meeting of Stockholders on May 7, 2026, where shareholders approved the election of nine directors, the advisory compensation of named executive officers, and ratified Deloitte & Touche LLP as the independent accounting firm. TipRanks' AI Analyst, Spark, rates AVTR as Neutral due to deteriorating profitability and shrinking revenue, despite resilient cash generation and reaffirmed guidance. The current analyst rating on AVTR stock is a Sell with a $7.00 price target.
Avantor forecasts Q2 adjusted EPS of $0.19-$0.20 while incorporating $10M-$20M inflation headwind
Avantor has released its second-quarter adjusted EPS forecast, expecting it to be between $0.19 and $0.20. This guidance incorporates a significant inflation headwind estimated at $10 million to $20 million. The company is navigating these economic challenges while providing its financial outlook.
[8-K] Avantor, Inc. Reports Material Event
Avantor, Inc. has reported the results of its 2026 Annual Meeting of Stockholders held on May 7, 2026. Shareholders elected nine directors, approved the 2025 executive compensation on an advisory basis, and ratified Deloitte & Touche LLP as the independent auditor for 2026. The company also confirmed an annual frequency for future advisory votes on executive compensation.
Avantor stock (US0543031027): Director Lucier buys $83,200 worth amid 31% yearly decline
Avantor director Gregory Lucier purchased 10,000 shares of the company's stock for $83,200 on May 7, 2026, marking an insider buy amidst a 31% decline in the stock's value over the past year. Avantor, a company providing crucial products and services to life sciences and biopharma sectors, benefits from expansion in bioprocessing and strong US market exposure. This move highlights insider confidence despite recent market volatility and reinforces the company's connection to ongoing biopharma growth trends.
Avantor (NYSE: AVTR) director buys 10K shares and receives RSU grant
Avantor (NYSE: AVTR) director Gregory T. Lucier recently acquired 10,000 shares through a trust at a weighted average price of $8.32, bringing the trust's indirect holdings to 60,000 shares. Additionally, Lucier received a grant of 25,270 restricted stock units (RSUs) as equity compensation, which will vest on May 7, 2027. Following these transactions, his direct holdings stand at 34,006 shares, and he disclaims beneficial ownership of the trust shares beyond his pecuniary interest.
Stock grant lifts Avantor (NYSE: AVTR) director Simon Dingemans’ holdings
Avantor director Simon Dingemans was granted 25,270 restricted stock units (RSUs) as part of his director compensation, which will vest on May 7, 2027. This transaction, reported via a Form 4 filing, increases his direct holdings in Avantor to 31,495 shares and was an equity award rather than an open market purchase. The grant was awarded at no cash price and reflects a routine stock-based component of his remuneration.
Avantor director Gregory Lucier buys $83,200 in company stock
Avantor director Gregory Lucier purchased 10,000 shares of the company's common stock for $83,200 on May 8, 2026. This insider buying occurred while the stock was trading significantly lower over the past year. Separately, Lucier also received 25,270 restricted stock units set to vest in 2027, and the company recently reported strong Q1 2026 financial results, exceeding analyst expectations for EPS and revenue.
Avantor (AVTR) director Mala Murthy granted 25,270 restricted stock units
Avantor (AVTR) director Mala Murthy was granted 25,270 restricted stock units on May 7, 2026, as reported in a Form 4 SEC filing. This equity award, part of her long-term compensation, vests on May 7, 2027, and increased her direct holdings in the company to 69,479 shares. The grant was made at no cash cost, distinguishing it from an open-market purchase.
Avantor (AVTR) director Louise Makin receives 25,270-share restricted stock grant
Avantor, Inc. director Louise Makin was granted 25,270 shares of common stock in the form of restricted stock units (RSUs) as part of her compensation. The RSUs were granted at a price of $0.00 per share and are scheduled to vest on May 7, 2027. Following this grant, Makin directly holds a total of 47,140 shares of Avantor common stock.
Avantor (AVTR) director Joseph Massaro granted 25,270 restricted stock units
Avantor (AVTR) director Joseph R. Massaro was granted 25,270 restricted stock units (RSUs) on May 7, 2026, as part of his compensation. These RSUs, which vest on May 7, 2027, were awarded at a price of $0.00 per share, indicating a non-market transaction. Following this grant, Massaro directly owns 77,408 shares of Avantor common stock.
Avantor shares jump 9% after Q1 earnings beat
Avantor (NYSE:AVTR) reported a strong first quarter, beating analyst estimates for both earnings and revenue. The company's adjusted EPS of $0.23 exceeded the consensus, while revenue of $1.67 billion also surpassed expectations. This positive financial performance led to a notable 9% increase in Avantor's share price.
Flat Q1 Margins At Avantor (AVTR) Could Be A Game Changer For Its Efficiency Story
Avantor (AVTR) reported flat Q1 2026 sales and reduced net income, highlighting pressure on its margins despite stable revenue. This performance raises questions about the effectiveness of its ongoing cost and efficiency initiatives. The appointment of Ludovic Brellier as EVP and Chief Transformation Officer signals a focus on margin improvement and risk management amidst pricing pressures and cost inflation.
Avantor (NYSE:AVTR) - Stock Analysis
This article provides a detailed stock analysis of Avantor (NYSE:AVTR), covering its valuation, growth prospects, past performance, financial health, and recent news. It highlights the company's Q1 2026 earnings beat, recent weak 2026 guidance leading to analyst downgrades, and ongoing challenges with organic growth and margin pressures, reflecting market skepticism despite the stock trading below its fair value. Recent insider buying and executive changes are also noted, alongside discussions of activist investor involvement urging strategic changes or a sale.
Avantor Reports Lower Q1 Profit, Reaffirms 2026 Guidance
Avantor, Inc. reported a lower Q1 2026 net income of $43.3 million, down from $64.5 million in the prior year, despite net sales of $1.58 billion remaining essentially unchanged. The company reaffirmed its fiscal 2026 guidance, with CEO Emmanuel Ligner noting that Q1 results exceeded expectations due to improved execution in Bioscience and Medtech Products and stabilization in VWR. Organic sales declined 4.1% overall, impacting both the VWR Distribution & Services and Bioscience & Medtech Products segments.
Bronstein, Gewirtz & Grossman, LLC Encourages Avantor, Inc. (AVTR) Shareholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of Avantor, Inc. (AVTR) shareholders who purchased securities prior to March 5, 2024, and continue to hold them. The investigation concerns potential corporate wrongdoing by Avantor's officers and/or directors. The firm encourages affected investors to contact them for more information, noting that they represent investors on a contingency fee basis.
Avantor (NYSE: AVTR) EVP Ludovic Brellier awarded RSUs and 246,002 stock options
Avantor, Inc. EVP Ludovic Brellier was granted 146,566 restricted stock units and 246,002 stock options as part of his compensation. These equity awards, which are not open-market transactions, will vest in three equal annual installments starting May 1, 2027. The stock options have an exercise price of $8.76 per share and expire on May 1, 2036.
Avantor director Simon Dingemans buys $203,500 in company stock
Avantor director Simon Dingemans acquired 25,000 shares of company stock for $203,500 on May 1, 2026, bringing his total indirect holdings to 25,000 shares and direct holdings to 6,225 shares. This purchase occurred after Avantor exceeded Q1 2026 financial expectations with an EPS of $0.17 and revenue of $1.581 billion, positively impacting investor sentiment despite a 36% stock price decline over the past year.
Avantor (AVTR) director adds 25,000 shares via open-market purchase
Avantor, Inc. (AVTR) director Simon Dingemans reported an open-market purchase of 25,000 shares of common stock at $8.14 per share, totaling $203,500. These shares are held indirectly by his spouse, in addition to his direct holding of 6,225 shares. The Form 4 filing confirmed this positive insider activity, indicating confidence from the director.
Avantor (NYSE: AVTR) EVP files initial Form 3 ownership
Avantor, Inc.'s Executive Vice President of Bioscience & Medtech, Ludovic Brellier, has filed an initial Form 3 with the SEC, establishing his status as an insider. The filing indicates his beneficial ownership of securities but reports no actual buy or sell transactions or derivative positions at this time. This initial report serves to disclose his relationship with the company rather than any trading activity.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Avantor, Inc. (AVTR) And Encourages Shareholders to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of Avantor, Inc. (AVTR) shareholders who purchased securities before March 5, 2024. The investigation aims to determine if Avantor's officers or directors engaged in corporate wrongdoing. Shareholders are encouraged to contact the firm for more information and to assist with the investigation, with no direct cost to them as the firm operates on a contingency fee basis.
Avantor Names Ludovic Brellier EVP of BMP and Chief Transformation Officer
Avantor, Inc. has appointed Ludovic Brellier as Executive Vice President of its Bioscience & Medtech Products (BMP) segment and Chief Transformation Officer, effective May 1, 2026. Brellier will lead the growth of the BMP business and direct enterprise-wide transformation initiatives, including through the Revival Management Office. He joins Avantor from Danaher, bringing a strong background in growing bioprocessing businesses.
Evercore Maintains Avantor(AVTR.US) With Hold Rating, Cuts Target Price to $8
Evercore has reiterated its Hold rating on Avantor (AVTR.US) but has reduced the target price to $8. This adjustment reflects a cautious outlook for the company's stock.
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Avantor, Inc. (AVTR) And Encourages Shareholders to Reach Out
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential claims against Avantor, Inc. (NYSE:AVTR) concerning corporate wrongdoing. The firm is encouraging shareholders who purchased Avantor securities before March 5, 2024, and still hold them, to come forward and assist with the investigation. Investors can find more information and contact the firm through their website or phone number.
William Blair Keeps Market Perform Rating on Avantor (AVTR) After CFO Departure
William Blair has reaffirmed its Market Perform rating on Avantor (AVTR) following the announcement of CFO Brent Jones' departure, which is set for on or before June 24. Despite this leadership change, Avantor has maintained its 2026 guidance, after having cut it twice in 2025 and providing an initial 2026 forecast that was below market expectations. The CFO transition aligns with a recent CEO change and the launch of Avantor's "Revival" turnaround program.
Precision Trading with Avantor Inc. (AVTR) Risk Zones
This article by Stock Traders Daily analyzes Avantor Inc. (AVTR), highlighting a near-term weak sentiment with a potential exceptional risk-reward setup targeting a 20.8% gain. It outlines specific trading strategies, including long, momentum breakout, and short positions, along with multi-timeframe signal analysis to manage risks. The analysis suggests a mid-channel oscillation pattern is in play, with AI models providing real-time entry and exit signals for traders.
Avantor, Inc. (NYSE:AVTR) Q1 2026 Earnings Call Transcript
Avantor, Inc. reported Q1 2026 earnings, beating expectations with an EPS of $0.17 against an anticipated $0.16. The company's "Revival" initiatives are showing positive impacts on execution and operational stability, particularly within the VWR Distribution and Services and Bioscience and Medtech Products (BMP) segments. Avantor reaffirmed its full-year guidance, anticipating a financial turnaround with VWR's growth rate having bottomed in Q1 and BMP's expected to bottom in Q2, positioning the company for organic revenue growth in the second half of 2026 despite inflationary pressures from the Middle East conflict.
Profits fall as Avantor (NYSE: AVTR) keeps 2026 outlook
Avantor (NYSE: AVTR) reported mixed first-quarter 2026 results with flat net sales of $1,581.4 million compared to the previous year, but organic net sales declined 4.1% due to foreign currency tailwinds. Profitability significantly decreased, with net income falling to $43.3 million from $64.5 million, and adjusted EBITDA dropping to $219.4 million with a 13.9% margin. Despite the weaker performance, the company reaffirmed its full-year 2026 financial guidance.
Vanguard holds 35.8M shares of Avantor (AVTR) in Schedule 13G
Vanguard Capital Management reported a beneficial ownership of 35,802,263 shares of Avantor Inc. (AVTR) common stock, representing a 5.29% stake, in a Schedule 13G filing. The filing indicates that Vanguard has sole dispositive power over all these shares and sole voting power over 5,196,151 shares. The disclosure also aggregates holdings from various Vanguard affiliated entities.
AMG National Trust Bank Invests $1.59 Million in Avantor, Inc. $AVTR
AMG National Trust Bank has initiated a new position in Avantor, Inc. (NYSE:AVTR), purchasing 138,313 shares valued at approximately $1.59 million in the fourth quarter. This move comes as Avantor insiders, including directors Sanjeev K. Mehra and Gregory T. Lucier, have also been actively buying shares worth over $2.399 million in the past three months. Analysts currently hold a consensus "Hold" rating on Avantor, with an average target price of $11.54, while the company issued FY2026 EPS guidance between $0.77 and $0.83.
Avantor’s (NYSE:AVTR) Q1 CY2026 Sales Beat Estimates
Avantor (NYSE:AVTR) reported Q1 CY2026 results, with sales of $1.58 billion beating analyst estimates by 2.7% and non-GAAP EPS of $0.17 exceeding consensus by 8.4%. Despite beating expectations for the quarter, the company has shown flat revenue growth over the last five years and a decline in EPS, raising concerns about its long-term growth and profitability. The stock traded up 4.2% immediately after the report, but analysts expect revenue to remain flat over the next 12 months.
Avantor Reports "Turning Point" in Q1 2026 as Revival Transformation Begins to Deliver
Avantor, Inc. reported better-than-expected Q1 2026 results, with revenue and earnings surpassing analyst estimates, driven by improved execution in its Bioscience and Medtech Products segment and early successes from its "Revival" transformation program. Despite organic sales declines, the company reaffirmed its full-year financial guidance, signaling confidence in its operational overhaul to improve supply chain stability and profitability. Lab managers and procurement professionals should closely monitor the impact of these changes on product availability, pricing, and new product launches from Avantor's growing BMP segment.
Earnings call transcript: Avantor Q1 2026 beats expectations, stock surges
Avantor Inc. reported strong Q1 2026 results, surpassing analyst expectations with an EPS of $0.17 and revenue of $1.581 billion, leading to a 6.49% surge in premarket trading. The company reaffirmed its full-year guidance, anticipating a return to organic revenue growth in the second half of 2026, driven by improvements in its Bioscience & Medtech Products (BMP) segment and ongoing digital transformation efforts. Management expressed confidence in the "Revival" initiatives, highlighting improved execution and stabilized operational performance across its segments.
Avantor Expands Masterflex Brand Across Fluid Handling Portfolio
Avantor, Inc. (NYSE: AVTR) has expanded its Masterflex brand to encompass its entire fluid handling portfolio, including pumps, assemblies, and systems used in bioprocessing and industrial applications. This unification aims to simplify system selection and integration for customers moving processes from development to production. The Masterflex portfolio now offers standard, configurable, and engineered-to-order peristaltic pumps, single-use assemblies, and integrated systems, supporting fluid transfer and system connectivity.
